Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization

Ahmad M. Mansour, J Fernando Arevalo, Christine Fardeau, Emily N. Hrisomalos, Wai Man Chan, Timothy Y Y Lai, Focke Ziemssen, Thomas Ness, Abla Mehio Sibai, Friederike MacKensen, Armin Wolf, Nicholas Hrisomalos, Arnd Heiligenhaus, Georg Spital, Yukari Jo, Fumi Gomi, Yasushi Ikuno, Jad Akesbi, Phuc LeHoang, Alfredo AdanPadmamalini Mahendradas, Moncef Khairallah, Rainer Guthoff, Blanche Ghandour, Cem Küçükerdönmez, Shree K. Kurup

Research output: Contribution to journalArticle

Abstract

Objective: To assess the 3-year visual outcome of intravitreal bevacizumab in inflammatory ocular neovascularization. Design: Experimental study. Methods: Retrospective multicenter consecutive case series in 81 patients with inflammatory ocular neovascularization refractory to standard therapy and treated with intravitreal bevacizumab. The outcome measures included improvement of best corrected visual acuity expressed as logarithm of minimum angle of resolution (logMAR) and paired comparison decrease in central foveal thickness by optical coherence tomography. Results: Mean best corrected visual acuity improved from baseline 0.699 (6/30 or 20/101) (SD 0.434) to 0.426 (6/16 or 20/53) (SD 0.428) (n = 81; p <0.001), a gain of 2.7 lines (median 3 injections; 81 eyes; 81 patients). Paired comparisons revealed significant central foveal flattening at 3 years of 97.9 μm (n = 51; p <0.001). In a subgroup analysis, visual improvement was significant for ocular histoplasmosis (p = 0.026); multifocal choroiditis (p = 0.05); serpiginous choroiditis (p = 0.028); ocular toxoplasmosis (p = 0.042); and punctate inner choroidopathy (p = 0.015). In a subgroup analysis, foveal flattening was significant for ocular histoplasmosis (p = 0.004); multifocal choroiditis (p = 0.007); serpiginous choroiditis (p = 0.011); and punctate inner choroidopathy (p = 0.001). Of the group, 5 eyes developed submacular fibrosis, 1 eye retinal pigment epithelial tear, and 1 eye macular ischemia in the context of vasculitis. Conclusion: At 3 years, intravitreal bevacizumab sustained significant visual improvement of 2.7 lines and significant foveal flattening of 98 μm in a wide variety of inflammatory ocular diseases without major complications after a median of 3 injections.

Original languageEnglish (US)
Pages (from-to)269-274
Number of pages6
JournalCanadian Journal of Ophthalmology
Volume47
Issue number3
DOIs
StatePublished - 2012

Fingerprint

Choroiditis
Matched-Pair Analysis
Histoplasmosis
Visual Acuity
Ocular Toxoplasmosis
Injections
Retinal Pigments
Eye Diseases
Bevacizumab
Optical Coherence Tomography
Vasculitis
Tears
Fibrosis
Research Design
Ischemia
Outcome Assessment (Health Care)
Multifocal choroiditis
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization. / Mansour, Ahmad M.; Arevalo, J Fernando; Fardeau, Christine; Hrisomalos, Emily N.; Chan, Wai Man; Lai, Timothy Y Y; Ziemssen, Focke; Ness, Thomas; Sibai, Abla Mehio; MacKensen, Friederike; Wolf, Armin; Hrisomalos, Nicholas; Heiligenhaus, Arnd; Spital, Georg; Jo, Yukari; Gomi, Fumi; Ikuno, Yasushi; Akesbi, Jad; LeHoang, Phuc; Adan, Alfredo; Mahendradas, Padmamalini; Khairallah, Moncef; Guthoff, Rainer; Ghandour, Blanche; Küçükerdönmez, Cem; Kurup, Shree K.

In: Canadian Journal of Ophthalmology, Vol. 47, No. 3, 2012, p. 269-274.

Research output: Contribution to journalArticle

Mansour, AM, Arevalo, JF, Fardeau, C, Hrisomalos, EN, Chan, WM, Lai, TYY, Ziemssen, F, Ness, T, Sibai, AM, MacKensen, F, Wolf, A, Hrisomalos, N, Heiligenhaus, A, Spital, G, Jo, Y, Gomi, F, Ikuno, Y, Akesbi, J, LeHoang, P, Adan, A, Mahendradas, P, Khairallah, M, Guthoff, R, Ghandour, B, Küçükerdönmez, C & Kurup, SK 2012, 'Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization', Canadian Journal of Ophthalmology, vol. 47, no. 3, pp. 269-274. https://doi.org/10.1016/j.jcjo.2012.03.042
Mansour, Ahmad M. ; Arevalo, J Fernando ; Fardeau, Christine ; Hrisomalos, Emily N. ; Chan, Wai Man ; Lai, Timothy Y Y ; Ziemssen, Focke ; Ness, Thomas ; Sibai, Abla Mehio ; MacKensen, Friederike ; Wolf, Armin ; Hrisomalos, Nicholas ; Heiligenhaus, Arnd ; Spital, Georg ; Jo, Yukari ; Gomi, Fumi ; Ikuno, Yasushi ; Akesbi, Jad ; LeHoang, Phuc ; Adan, Alfredo ; Mahendradas, Padmamalini ; Khairallah, Moncef ; Guthoff, Rainer ; Ghandour, Blanche ; Küçükerdönmez, Cem ; Kurup, Shree K. / Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization. In: Canadian Journal of Ophthalmology. 2012 ; Vol. 47, No. 3. pp. 269-274.
@article{8d66543059934b819666167b4e1b47f2,
title = "Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization",
abstract = "Objective: To assess the 3-year visual outcome of intravitreal bevacizumab in inflammatory ocular neovascularization. Design: Experimental study. Methods: Retrospective multicenter consecutive case series in 81 patients with inflammatory ocular neovascularization refractory to standard therapy and treated with intravitreal bevacizumab. The outcome measures included improvement of best corrected visual acuity expressed as logarithm of minimum angle of resolution (logMAR) and paired comparison decrease in central foveal thickness by optical coherence tomography. Results: Mean best corrected visual acuity improved from baseline 0.699 (6/30 or 20/101) (SD 0.434) to 0.426 (6/16 or 20/53) (SD 0.428) (n = 81; p <0.001), a gain of 2.7 lines (median 3 injections; 81 eyes; 81 patients). Paired comparisons revealed significant central foveal flattening at 3 years of 97.9 μm (n = 51; p <0.001). In a subgroup analysis, visual improvement was significant for ocular histoplasmosis (p = 0.026); multifocal choroiditis (p = 0.05); serpiginous choroiditis (p = 0.028); ocular toxoplasmosis (p = 0.042); and punctate inner choroidopathy (p = 0.015). In a subgroup analysis, foveal flattening was significant for ocular histoplasmosis (p = 0.004); multifocal choroiditis (p = 0.007); serpiginous choroiditis (p = 0.011); and punctate inner choroidopathy (p = 0.001). Of the group, 5 eyes developed submacular fibrosis, 1 eye retinal pigment epithelial tear, and 1 eye macular ischemia in the context of vasculitis. Conclusion: At 3 years, intravitreal bevacizumab sustained significant visual improvement of 2.7 lines and significant foveal flattening of 98 μm in a wide variety of inflammatory ocular diseases without major complications after a median of 3 injections.",
author = "Mansour, {Ahmad M.} and Arevalo, {J Fernando} and Christine Fardeau and Hrisomalos, {Emily N.} and Chan, {Wai Man} and Lai, {Timothy Y Y} and Focke Ziemssen and Thomas Ness and Sibai, {Abla Mehio} and Friederike MacKensen and Armin Wolf and Nicholas Hrisomalos and Arnd Heiligenhaus and Georg Spital and Yukari Jo and Fumi Gomi and Yasushi Ikuno and Jad Akesbi and Phuc LeHoang and Alfredo Adan and Padmamalini Mahendradas and Moncef Khairallah and Rainer Guthoff and Blanche Ghandour and Cem K{\"u}{\cc}{\"u}kerd{\"o}nmez and Kurup, {Shree K.}",
year = "2012",
doi = "10.1016/j.jcjo.2012.03.042",
language = "English (US)",
volume = "47",
pages = "269--274",
journal = "Canadian Journal of Ophthalmology",
issn = "0008-4182",
publisher = "Canadian Ophthalmological Society",
number = "3",

}

TY - JOUR

T1 - Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization

AU - Mansour, Ahmad M.

AU - Arevalo, J Fernando

AU - Fardeau, Christine

AU - Hrisomalos, Emily N.

AU - Chan, Wai Man

AU - Lai, Timothy Y Y

AU - Ziemssen, Focke

AU - Ness, Thomas

AU - Sibai, Abla Mehio

AU - MacKensen, Friederike

AU - Wolf, Armin

AU - Hrisomalos, Nicholas

AU - Heiligenhaus, Arnd

AU - Spital, Georg

AU - Jo, Yukari

AU - Gomi, Fumi

AU - Ikuno, Yasushi

AU - Akesbi, Jad

AU - LeHoang, Phuc

AU - Adan, Alfredo

AU - Mahendradas, Padmamalini

AU - Khairallah, Moncef

AU - Guthoff, Rainer

AU - Ghandour, Blanche

AU - Küçükerdönmez, Cem

AU - Kurup, Shree K.

PY - 2012

Y1 - 2012

N2 - Objective: To assess the 3-year visual outcome of intravitreal bevacizumab in inflammatory ocular neovascularization. Design: Experimental study. Methods: Retrospective multicenter consecutive case series in 81 patients with inflammatory ocular neovascularization refractory to standard therapy and treated with intravitreal bevacizumab. The outcome measures included improvement of best corrected visual acuity expressed as logarithm of minimum angle of resolution (logMAR) and paired comparison decrease in central foveal thickness by optical coherence tomography. Results: Mean best corrected visual acuity improved from baseline 0.699 (6/30 or 20/101) (SD 0.434) to 0.426 (6/16 or 20/53) (SD 0.428) (n = 81; p <0.001), a gain of 2.7 lines (median 3 injections; 81 eyes; 81 patients). Paired comparisons revealed significant central foveal flattening at 3 years of 97.9 μm (n = 51; p <0.001). In a subgroup analysis, visual improvement was significant for ocular histoplasmosis (p = 0.026); multifocal choroiditis (p = 0.05); serpiginous choroiditis (p = 0.028); ocular toxoplasmosis (p = 0.042); and punctate inner choroidopathy (p = 0.015). In a subgroup analysis, foveal flattening was significant for ocular histoplasmosis (p = 0.004); multifocal choroiditis (p = 0.007); serpiginous choroiditis (p = 0.011); and punctate inner choroidopathy (p = 0.001). Of the group, 5 eyes developed submacular fibrosis, 1 eye retinal pigment epithelial tear, and 1 eye macular ischemia in the context of vasculitis. Conclusion: At 3 years, intravitreal bevacizumab sustained significant visual improvement of 2.7 lines and significant foveal flattening of 98 μm in a wide variety of inflammatory ocular diseases without major complications after a median of 3 injections.

AB - Objective: To assess the 3-year visual outcome of intravitreal bevacizumab in inflammatory ocular neovascularization. Design: Experimental study. Methods: Retrospective multicenter consecutive case series in 81 patients with inflammatory ocular neovascularization refractory to standard therapy and treated with intravitreal bevacizumab. The outcome measures included improvement of best corrected visual acuity expressed as logarithm of minimum angle of resolution (logMAR) and paired comparison decrease in central foveal thickness by optical coherence tomography. Results: Mean best corrected visual acuity improved from baseline 0.699 (6/30 or 20/101) (SD 0.434) to 0.426 (6/16 or 20/53) (SD 0.428) (n = 81; p <0.001), a gain of 2.7 lines (median 3 injections; 81 eyes; 81 patients). Paired comparisons revealed significant central foveal flattening at 3 years of 97.9 μm (n = 51; p <0.001). In a subgroup analysis, visual improvement was significant for ocular histoplasmosis (p = 0.026); multifocal choroiditis (p = 0.05); serpiginous choroiditis (p = 0.028); ocular toxoplasmosis (p = 0.042); and punctate inner choroidopathy (p = 0.015). In a subgroup analysis, foveal flattening was significant for ocular histoplasmosis (p = 0.004); multifocal choroiditis (p = 0.007); serpiginous choroiditis (p = 0.011); and punctate inner choroidopathy (p = 0.001). Of the group, 5 eyes developed submacular fibrosis, 1 eye retinal pigment epithelial tear, and 1 eye macular ischemia in the context of vasculitis. Conclusion: At 3 years, intravitreal bevacizumab sustained significant visual improvement of 2.7 lines and significant foveal flattening of 98 μm in a wide variety of inflammatory ocular diseases without major complications after a median of 3 injections.

UR - http://www.scopus.com/inward/record.url?scp=84862285277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862285277&partnerID=8YFLogxK

U2 - 10.1016/j.jcjo.2012.03.042

DO - 10.1016/j.jcjo.2012.03.042

M3 - Article

C2 - 22687305

AN - SCOPUS:84862285277

VL - 47

SP - 269

EP - 274

JO - Canadian Journal of Ophthalmology

JF - Canadian Journal of Ophthalmology

SN - 0008-4182

IS - 3

ER -